Ani Pharmaceuticals (ANIP) EBT (2011 - 2026)

Ani Pharmaceuticals has disclosed EBT across 16 years of filings, most recently posting $40.2 million for Q1 2026.

• EBT for Q1 2026 came in at $40.2 million, up 101.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $116.0 million (up 520.99% YoY), and the FY2025 annual result was $95.8 million, up 531.26% from the prior year.
• EBT came in at $40.2 million for Q1 2026 at Ani Pharmaceuticals, up from $31.5 million in the prior quarter.
• In the past five years, EBT ranged from a high of $40.2 million in Q1 2026 to a low of -$31.5 million in Q3 2024.
• The 5-year median for EBT is $2.2 million (2023), against an average of $4.2 million.
• Across the five-year window, EBT tumbled 34175.0% in 2022 and jumped 1070.21% in 2024, its largest moves.
• Ani Pharmaceuticals' EBT stood at -$5.7 million in 2022, then jumped by 116.53% to $947000.0 in 2023, then tumbled by 1553.22% to -$13.8 million in 2024, then surged by 328.74% to $31.5 million in 2025, then gained by 27.77% to $40.2 million in 2026.
• The last three EBT figures came in at $40.2 million (Q1 2026), $31.5 million (Q4 2025), and $33.8 million (Q3 2025), per Business Quant data.